J. Capdevila

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

G. Canaud, M. Caplin, E. Wolin, 2014 .

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

R. Salazar, R. Riechelmann, E. Van Cutsem, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

P. Nuciforo, S. Bullman, J. Tabernero, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

T. Halfdanarson, P. Aimone, C. Yoo, 2024, Journal of Clinical Oncology.

Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509).

A. L. Casta, J. Hernando, A. Teule, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.